Eli Lilly announces Verzenio survival benefit
Breast cancer is the most common cancer in women worldwide, with more than two million new cases diagnosed in 2018.
Read More
Tag: Verzenio
NICE nod for breast cancer delay drug
Eli Lilly’s Verzenio has been recommended for use within the Cancer Drugs Fund by NICE.
Read More
Lilly’s Verzenio bags third breast cancer nod
Eli Lilly’s Verzenio has been given another green light in the US for breast cancer, significantly expanding the drug’s treatment scope.
Read More
Lilly’s Verzenio misses key survival goal in lung cancer
Eli Lilly’s breast cancer drug Verzenio has failed to improve overall survival in a late-stage study assessing the drug’s potential in patients with KRAS-mutated, advanced non-small lung cancer (NSCLC).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
